Objectives: To investigate the support needs of patients with gout regarding information, communication, treatment and disease monitoring, and patients' views on and preferences for eHealth applications to address these needs.
Methods: A focus group study using purposive sampling was conducted. Three focus group sessions with a duration of 2 h per group were held with in total of 23 patients using urate-lowering therapy, recruited from primary and secondary care. Audio recordings were transcribed, and data were analysed using thematic analysis.
Results: Eight themes were identified. Five themes addressed support needs of gout patients and suitability of eHealth in addressing those needs: (1) Timely access to healthcare, especially during flares; (2) (personalized) information regarding diagnosis, medication, and diet; (3) insight into uric acid levels and medication side effects through blood monitoring; (4) better coordination across primary and secondary care; and (5) self-management and shared responsibility over care for maintaining health. Three themes addressed eHealth in general: (1) receptive towards eHealth in gout care; (2) the preference for eHealth to have a complementary role (i.e. not replacing face-to-face) contact with healthcare providers; and (3) preferences on eHealth use and functionalities.
Conclusion: Patients expressed various needs regarding their disease management and projected a supporting role for eHealth in (self)management of gout. Addressing the needs and preferences of patients could enhance their understanding of the disease and treatment, self-management, and possibly health outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494372 | PMC |
| http://dx.doi.org/10.1093/rap/rkae125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Digital Tool for Clinical Evidence-Driven Guideline Development by Studying Properties of Trial Eligible and Ineligible Populations: Development and Usability Study.
J Med Internet Res
January 2025
Advanced Care Research Centre, Usher Institute, The University of Edinburgh, Edinburgh, United Kingdom.
Background: Clinical guideline development preferentially relies on evidence from randomized controlled trials (RCTs). RCTs are gold-standard methods to evaluate the efficacy of treatments with the highest internal validity but limited external validity, in the sense that their findings may not always be applicable to or generalizable to clinical populations or population characteristics. The external validity of RCTs for the clinical population is constrained by the lack of tailored epidemiological data analysis designed for this purpose due to data governance, consistency of disease or condition definitions, and reduplicated effort in analysis code.
View Article and Find Full Text PDFSuccessful Treatment of Adventitious Bursitis With Marginal Resection in a 23-Year-Old Patient: A Case Report.
Cureus
December 2024
Department of Orthopedics and Traumatology, Cerrahpasa Faculty of Medicine, Istanbul University - Cerrahpasa, Istanbul, TUR.
Adventitious bursitis is an inflammatory condition affecting bursae. Distinct from primary or infectious bursitis, adventitious bursitis typically develops secondary to conditions such as rheumatoid arthritis, gout, or repetitive joint overuse. The resulting inflammation can lead to pain, swelling, and restricted mobility, significantly impacting patients' quality of life.
View Article and Find Full Text PDFInvestigating the Role of Food-Derived Peptides in Hyperuricemia: From Mechanisms of Action to Structural Effects.
Foods
December 2024
Key Laboratory of Geriatric Nutrition and Health, Beijing Technology and Business University, Ministry of Education, Beijing 100048, China.
Hyperuricemia, a disorder of purine metabolism associated with cardiovascular disease, gout, and kidney disease, can be alleviated by food-derived peptides. However, the precise mechanisms remain unclear, hindering their development. This study reviews uric acid-lowering peptides from various sources, focusing on two pathways: inhibiting uric acid production and promoting excretion.
View Article and Find Full Text PDFNose-to-brain delivery of DHA-loaded nanoemulsions: A promising approach against Alzheimer's disease.
Int J Pharm
January 2025
MMDN, University of Montpellier, EPHE, INSERM, Montpellier, France; LipSTIC LabEx (ANR-11-LABX0021), Dijon, France. Electronic address:
Reduced docosahexaenoic acid (DHA) concentrations seem to be associated with an increased risk of Alzheimer's disease (AD), and DHA accretion to the brain across the blood-brain-barrier (BBB) can be modulated by various factors. Therefore, there is an urgent need to identify an efficient and non-invasive method to ensure brain DHA enrichment. In the present study, a safe and stable DHA-enriched nanoemulsion, designed to protect DHA against oxidation, was designed and administered intranasally in a transgenic mouse model of AD, the J20 mice.
View Article and Find Full Text PDFAssociation between urate-lowering therapy and kidney failure in patients with chronic kidney disease.
J Nephrol
January 2025
Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, CHU Amiens-Picardie, Rond-Point du Professeur Christian Cabrol, 80054, Amiens Cedex, France.
Background: Hyperuricemia is a hallmark of gout and a suspected risk factor for the progression of chronic kidney disease (CKD). However, the impact of urate-lowering therapy on CKD progression is subject to debate. The objective of the present study was to describe the prevalence of inappropriate urate-lowering therapy prescriptions and evaluate the association between urate-lowering therapy prescription and the progression of kidney disease in patients with CKD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!